CAESAREA, Israel, April 20, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by ...

Use of the ProSense Cryoablation System in patients with kidney cancer resulted in an 83.9% recurrence-free rate among 112 ...

$6.6 million in sales expected in Brazilian market over the next five years per distribution agreement guarantees High level of early interest in ProSense in South America's largest market ProSense's ...

CAESAREA, Israel, Aug. 21, 2023 /PRNewswire/ -- IceCure Medical LTD. (ICCM) (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology ...

IceCure Medical Ltd. (NASDAQ:ICCM), the developer of minimally invasive cryoablation technology that destroys tumors by freezing them, was granted marketing authorization from the U.S. Food and Drug ...

Fibroadenoma is the most common benign breast lesion identified through core needle biopsy. Up to 10% of women will have a fibroadenoma at some point in their lives, according to the Cleveland Clinic.

CAESAREA, Israel, Feb. 15, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that ...

"Thomas Hospital and Infirmary Health are leading the advancement of breast care in Alabama, where they serve a large population of women from around the Gulf Coast region. We are very pleased that ...